PCSK9 and Atrial Fibrillation: A New Perspective on an Old Problem
Cardiovascular Therapeutics · 2026
DOI: 10.1155/cdr/7328020 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cardiovascular Therapeutics, 2026. Verfasst von Amirhossein Sahebkar und 3 weiteren Autor:innen. Beteiligte Einrichtung: Biotechnology Research Center, Pharmaceutical Technology Institute, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran, mums.a…. Hauptthemen laut MEDLINE: Atrial Fibrillation, Proprotein Convertase 9, Dyslipidemias. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Iran National Science Foundation.
Abstract (Originalsprache)
Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a novel contributor to atrial fibrillation (AF) pathophysiology. Recent studies suggest that elevated PCSK9 levels may promote AF through multiple mechanisms, including platelet activation, oxidative stress, vascular calcification, and structural atrial remodeling. PCSK9 inhibitors such as alirocumab, evolocumab, and newer agents like inclisiran have shown potential in reducing AF incidence and cardiovascular events, particularly in high‐risk populations. However, evidence from randomized controlled trials with AF as a primary clinical endpoint is limited. Further mechanistic and interventional research is warranted to establish optimized therapeutic strategies targeting PCSK9 in AF prevention and management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biotechnology Research Center, Pharmaceutical Technology Institute, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran, mums.ac.ir.
- Centre for Research Impact & Outcome, Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, India, chitkara.edu.in.
- Applied Biomedical Research Center, Basic Sciences Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran, mums.ac.ir.
- Heart and Vascular Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, UAE, clevelandclinicabudhabi.ae.
- Next-Generation Translational Nanomedicine Laboratory, Department of Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya (A Central University), Sagar, Madhya Pradesh, India.
- University Institute of Pharma Sciences, Chandigarh University, Mohali, Punjab, India, chandigarhuniversity.ac.in.
ORCID-Profile: Amirhossein Sahebkar, Wael Almahmeed, Prashant Kesharwani, Tannaz Jamialahmadi
Förderung
- Iran National Science Foundation
Zitieren
APA
Sahebkar, A., Almahmeed, W., Kesharwani, P., & Jamialahmadi, T. (2026). PCSK9 and Atrial Fibrillation: A New Perspective on an Old Problem. Cardiovascular Therapeutics. https://doi.org/10.1155/cdr/7328020
Vancouver
Sahebkar A, Almahmeed W, Kesharwani P, Jamialahmadi T. PCSK9 and Atrial Fibrillation: A New Perspective on an Old Problem. Cardiovascular Therapeutics. 2026. doi:10.1155/cdr/7328020
BibTeX
@article{Sahebkar2026,
author = {Sahebkar, Amirhossein and Almahmeed, Wael and Kesharwani, Prashant and Jamialahmadi, Tannaz},
title = {PCSK9 and Atrial Fibrillation: A New Perspective on an Old Problem},
journal = {Cardiovascular Therapeutics},
year = {2026},
doi = {10.1155/cdr/7328020}
}
EUVIMED